Rob Ellis

Castle Biosciences Area Manager: CT & RI Dermatology, Medical & Surgical Oncology

Role: Area Manager at Castle Biosciences, Inc.
Location: North Kingstown, RI, US
LinkedIn followers: 500 followers

About Rob Ellis

Providing clinical education and consultative implementation of (DecisionDx-Melanoma) and (DecisionDx-Squamous Cell Carcinoma) in the States of CT and RI-Supporting clinicians who manage and treat high-risk skin cancers by utilizing prognostic gene expression testing to better risk stratify and treat patients more precisely based on their individual tumor biology.

Experience

Area Manager
Castle Biosciences, Inc.
Nov 2022 — Present · CT, US
Area Manager for DecisionDx-Melanoma and DecisionDx-SCC in the States of Connecticut and Rhode Island.

Education

Coláiste Mhuire Marino
Irish Studies
1998 — 1998
Iona College
BA, Academic Scholarship
1996 — 2000
Bishop Hendricken High School
High School Diploma, National Honor Society
1992 — 1996

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@castlebiosciences.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Castle Biosciences, Inc.

Biotechnology Research · 781 employees · Founded 2008 · Friendswood, Texas, United States

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets five proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, and uveal melanoma. DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

castlebiosciences.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Rob Ellis

Experience

Area Manager

Education

Coláiste Mhuire Marino

Iona College

Bishop Hendricken High School

Find verified contacts for anyone on LinkedIn